Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
NCT06603155 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL
Last updated 2025-12-19
Summary
The purpose of this study is to evaluate whether Time Restricted Eating (TRE) can improve responses in participants with metastatic head and neck squamous cell cancer (mHNSCC) or unresectable/metastatic renal cell carcinoma (RCC) receiving Immune Checkpoint Blockers (ICB) by changing the gut microbiome (the bacteria and other microorganisms living in individual's bodies). A particular focus of this study is to compare the outcomes of African American participants when compared to the rest of the participant population. TRE is a form of intermittent fasting where food and drink intake is limited to a specific time window during the day. The information learned from this study may help researchers develop new strategies to improve outcomes in patients with mHNSCC and RCC in the future.
Participants will be asked to complete a dietary survey at baseline and week 9 and provide a baseline stool and blood sample. Two weeks before beginning ICB and after participants completed the baseline assessments, they will begin TRE. TRE will be defined as limiting food and drink intake to a 10 hour window during each day and fasting for 14 hours at night. Participants will be asked to complete a daily food log to document the times they eat and drink. On day 1 of ICB and weeks 3, 6, 9, 26, and 52 after ICB, participants will be asked to collect a blood sample and a toxicity assessment will be performed. On day 1 of ICB and weeks 9, 26, and 52 of ICB, participants will be asked to provide a stool sample. Participants will also undergo tumor imaging throughout the study as part of their standard of care assessments. If a participant's disease progresses after ICB, they will repeat all study assessments and be withdrawn from the study.
Conditions
- Metastatic Head-and-neck Squamous-cell Carcinoma
- Unresectable Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
Interventions
- BEHAVIORAL
-
Time restricted eating (TRE)
TRE is defined as limiting daily food intake to 10 hour period with a nightly fasting period of 14 hours.
Sponsors & Collaborators
- lead OTHER
Principal Investigators
-
Daniel George, MD · Duke University
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-30
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- United States
Study Locations
More Related Trials
-
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
NCT03109015 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
NCT05858749 ·Status: COMPLETED
-
Follow-up After Metastasectomy in Patients With Kidney Cancer
NCT00918775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PS-341 in Treating Patients With Metastatic Kidney Cancer
NCT00025376 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC
NCT02315755 ·Status: COMPLETED
-
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
NCT06716853 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma
NCT00494091 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
NCT00045370 ·Status: COMPLETED ·Phase: PHASE1
-
Consolidative Metastasis and Primary Directed Therapy (MPDT) for Renal Cell Carcinoma (RCC)
NCT06770855 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Interferon Alfa in Treating Patients With Advanced Kidney Cancer
NCT00003542 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.
NCT02398552 ·Status: UNKNOWN ·Phase: PHASE2
-
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone in Metastatic Renal Cell Carcinoma Patients
NCT03379012 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT05119335 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
PEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
NCT00045279 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
NCT04353765 ·Status: COMPLETED
-
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
NCT01182142 ·Status: COMPLETED ·Phase: PHASE2
-
An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies
NCT01457118 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy in Treating Patients With Advanced Kidney Cancer
NCT00011973 ·Status: COMPLETED ·Phase: PHASE2
-
Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib
NCT03129724 ·Status: UNKNOWN
-
Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib
NCT00890110 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
NCT01122615 ·Status: COMPLETED ·Phase: PHASE1
-
Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
NCT00039429 ·Status: COMPLETED ·Phase: PHASE2
-
Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
NCT03097328 ·Status: COMPLETED ·Phase: PHASE2
-
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
NCT00121251 ·Status: COMPLETED ·Phase: PHASE1/PHASE2